DSIP: Research, Mechanism of Action & Scientific Overview

What Is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was first isolated in 1977 by Swiss researchers Monnier and Schoenenberger from the cerebral venous blood of rabbits undergoing electrically-induced slow-wave sleep. The peptide was named for its observed ability to induce delta-wave activity, the deep, slow-wave stage of sleep, in research animals.

Despite more than four decades of investigation, DSIP remains one of the more enigmatic neuropeptides in the scientific literature. Its small size, broad tissue distribution, and apparent involvement in multiple biological processes, including sleep regulation, stress response, thermoregulation, and neuroendocrine signaling, have made it a continued subject of preclinical research.

Key Identifier

Peptide Profile

Full Name: Delta Sleep-Inducing Peptide
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular Weight: 848.81 g/mol
CAS Number: 62568-57-4
Classification: Nonapeptide, neuromodulator

Mechanism of Action

The precise mechanism by which DSIP exerts its observed biological effects has not been fully elucidated. Research to date suggests that DSIP operates through multiple pathways rather than a single dedicated receptor system.

Neuroendocrine Modulation

DSIP has been studied for its apparent influence on the hypothalamic-pituitary-adrenal (HPA) axis. Preclinical research has reported modulatory effects on corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH), two central regulators of the body's stress response. These observations have supported continued interest in DSIP's role as a potential endogenous stress-buffer.

Sleep Architecture Influence

Early studies observed that DSIP administration in research animals was associated with increased delta-wave electroencephalographic (EEG) activity, a hallmark of deep, restorative sleep. Subsequent investigations have produced mixed findings, with some studies confirming sleep-promoting effects and others finding little to no influence on sleep parameters, highlighting the complexity of DSIP's involvement in sleep regulation.

Antioxidant and Neuroprotective Activity

Research has examined DSIP's potential antioxidant properties, with preclinical studies reporting reductions in markers of oxidative stress and lipid peroxidation under various experimental conditions. These findings have contributed to investigation of DSIP as a potential neuroprotective candidate in models involving oxidative injury.

Thermoregulatory and Analgesic Effects

Studies in rodent models have reported modulatory effects of DSIP on body temperature regulation and nociceptive (pain) thresholds. While the underlying mechanisms are not fully understood, these observations suggest DSIP may interact with central autonomic and pain-modulating pathways.

Research Overview

DSIP has been the subject of scientific investigation since the late 1970s, with research spanning sleep science, stress biology, oncology, and neurology. The table below summarizes major research domains.

Research Area	Key Findings	Study Type
Sleep Regulation	Early studies reported increased delta-wave EEG activity following DSIP administration; later findings have been more variable	In vivo (rodent, rabbit)
Stress Response	Observed attenuation of stress-induced changes in cortisol, ACTH, and behavioral anxiety markers	In vivo (rodent)
Oxidative Stress	Preclinical studies have reported reductions in lipid peroxidation and antioxidant enzyme normalization	In vivo / In vitro
Neuroprotection	Research has observed protective effects in models of neuronal damage and excitotoxicity	In vivo (rodent)
Thermoregulation	Studies suggest modulation of core body temperature under hyper- and hypothermic challenge	In vivo (rodent)
Oncology (Preclinical)	Limited preclinical investigation has examined effects on cellular proliferation and tumor models	In vitro / In vivo

Research Context

DSIP remains understudied in modern clinical research compared to many other peptides. The majority of mechanistic and efficacy data comes from preclinical models published between the late 1970s and 1990s, with sporadic follow-up research since. Findings from animal studies do not necessarily translate directly to human outcomes, and further rigorous clinical investigation is needed.

Common Areas of Research Interest

The scientific interest in DSIP spans several distinct research domains. The following areas represent the most active applications in the published literature.

Sleep architecture, DSIP has been investigated in connection with slow-wave (delta) sleep regulation and circadian rhythm research
Stress response, Research has examined the peptide's apparent capacity to modulate HPA-axis activity and stress-related hormonal output
Neuroprotection, Studies have explored protective effects in neuronal injury models involving oxidative and excitotoxic insults
Chronic pain models, Preclinical research has investigated effects on nociception and analgesic thresholds
Withdrawal and dependence, Limited research has examined DSIP's role in attenuating signs of opioid or alcohol withdrawal in rodent models
Cellular protection, Investigations have studied its potential antioxidant activity at the cellular level

Pharmacokinetics

Pharmacokinetic data on DSIP are limited, and the available literature presents variable estimates. The peptide is known to cross the blood-brain barrier, a characteristic that has been cited frequently in support of its central nervous system research applications.

~7 min

Estimated Plasma Half-Life

Yes

Crosses BBB

849

Molecular Weight (Da)

Amino Acid Residues

A notable pharmacokinetic observation is DSIP's rapid plasma clearance. Despite its short systemic half-life, behavioral and EEG effects reported in preclinical studies have been observed over substantially longer durations, suggesting that peripheral plasma levels may not fully reflect central biological activity. This apparent disconnect between pharmacokinetics and pharmacodynamics remains an active area of discussion in the literature.

Comparison to Similar Peptides

DSIP is often considered alongside other neuropeptides with overlapping research applications, particularly those investigated for effects on sleep, stress, and neuroprotection.

Feature	DSIP	Selank	Semax
Origin	Rabbit cerebral venous blood (1977)	Synthetic analog of tuftsin	Synthetic analog of ACTH fragment
Primary Research Focus	Sleep, stress, neuroprotection	Anxiolytic, cognitive, immune	Cognitive enhancement, neuroprotection
Amino Acids	9	7	7
BBB Penetration	Yes	Yes	Yes

Frequently Asked Questions

What does DSIP stand for?

DSIP stands for Delta Sleep-Inducing Peptide, named for the delta-wave EEG activity observed in early rabbit research following its administration.

When was DSIP first discovered?

DSIP was first isolated and characterized in 1977 by researchers Monnier and Schoenenberger at the University of Basel, Switzerland.

Is DSIP naturally occurring?

Yes. DSIP is an endogenous peptide that has been identified in various mammalian tissues, including the brain, gastrointestinal tract, and peripheral circulation. It is not produced exclusively in a single tissue.

Does DSIP have an identified receptor?

No specific high-affinity receptor for DSIP has been conclusively identified as of current research. Its biological effects appear to be mediated through multiple interacting pathways rather than a single dedicated receptor.

What is the current status of DSIP human research?

Human clinical research on DSIP remains limited, particularly by modern standards. Most of the available data comes from preclinical animal studies conducted between the late 1970s and the 1990s, with occasional follow-up investigations since.

Is DSIP considered safe in research?

In preclinical literature, DSIP has generally been characterized as well-tolerated in research settings. However, long-term human safety data is not well established, and the peptide remains sold strictly for research and laboratory use.

Sources & References

Schoenenberger GA, Monnier M. "Characterization of a delta-electroencephalogram (-sleep)-inducing peptide." Proceedings of the National Academy of Sciences. 1977;74(3):1282-1286. PubMed
Kovalzon VM, Strekalova TV. "Delta sleep-inducing peptide (DSIP): A still unresolved riddle." Journal of Neurochemistry. 2006;97(2):303-309. PubMed
Graf MV, Kastin AJ. "Delta-sleep-inducing peptide (DSIP): An update." Peptides. 1986;7(6):1165-1187.
Khvatova EM, et al. "Effect of DSIP on the oxidative phosphorylation in the brain mitochondria under conditions of hypoxia." Bulletin of Experimental Biology and Medicine. 2003;135(3):240-242. PubMed
Sudakov KV, et al. "Delta-sleep inducing peptide (DSIP) as a factor facilitating animals' adaptation to acute stress." Stress. 1995;1(1):17-25.
Pollard BJ, Pomfrett CJ. "Delta sleep-inducing peptide." European Journal of Anaesthesiology. 2001;18(7):419-422.

Explore DSIP

Available for research purposes. Third-party tested for purity and identity.

View DSIP Products — $75

This product is intended for research and laboratory use only. It is not intended for human consumption.

Disclaimer: This content is provided for educational and informational purposes only. It is not intended as medical advice, nor does it constitute a recommendation for the treatment, cure, or prevention of any disease or condition. DSIP is sold for research purposes only and is not intended for human consumption. Always consult a qualified healthcare professional before making decisions about your health. Somata Peptides does not claim that any products treat, cure, or prevent any disease.

DSIP: Delta Sleep-Inducing Peptide